John R Teerlink Selected Research

Aspirin (Acetylsalicylic Acid)

4/2019	Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.
1/2017	Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure.
1/2017	Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial.
10/2016	CHA2 DS2 -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm.
1/2016	Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial.
1/2016	The first prognostic model for stroke and death in patients with systolic heart failure.
9/2015	Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin.
5/2015	Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.
1/2014	Cognitive function in ambulatory patients with systolic heart failure: insights from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.
1/2014	Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John R Teerlink Research Topics

Disease

189	Heart Failure 05/2022 - 05/2002
17	Dyspnea (Shortness of Breath) 01/2019 - 02/2003
14	Renal Insufficiency (Renal Failure) 01/2020 - 04/2009
9	Stroke (Strokes) 12/2019 - 03/2012
8	Systolic Heart Failure 01/2021 - 08/2011
7	Weight Loss (Weight Reduction) 01/2022 - 04/2010
7	Hypertension (High Blood Pressure) 01/2018 - 12/2009
6	Myocardial Infarction 01/2022 - 03/2002
6	Heart Diseases (Heart Disease) 03/2021 - 10/2013
6	Hypotension (Low Blood Pressure) 01/2020 - 07/2003
6	Ischemic Stroke 10/2016 - 05/2012
5	Disease Progression 01/2021 - 10/2010
5	Ischemia 01/2017 - 11/2004
5	Left Ventricular Dysfunction 02/2015 - 06/2006
4	Ventricular Remodeling 01/2017 - 12/2002
4	Hemorrhage 09/2015 - 05/2012
3	Atrial Fibrillation 01/2022 - 02/2012
3	Cardiomyopathies (Cardiomyopathy) 01/2022 - 11/2017
3	Cardiac Arrhythmias (Arrythmia) 08/2021 - 04/2013
3	Cardiovascular Diseases (Cardiovascular Disease) 06/2019 - 01/2016
3	Inflammation (Inflammations) 10/2017 - 10/2016
3	Edema (Dropsy) 08/2017 - 11/2007
3	Cerebral Hemorrhage 01/2016 - 01/2013
2	Cardiogenic Shock 08/2021 - 01/2019
2	Low Cardiac Output 01/2019 - 10/2011
2	Body Weight (Weight, Body) 01/2019 - 05/2011
2	Diabetes Mellitus 10/2017 - 01/2016

Drug/Important Bio-Agent (IBA)

24	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 10/2006
19	DiureticsIBA 01/2022 - 05/2004
19	Biomarkers (Surrogate Marker)IBA 03/2021 - 02/2003
18	omecamtiv mecarbilIBA 05/2022 - 12/2009
14	rolofyllineIBA 11/2019 - 10/2010
13	Cardiac MyosinsIBA 01/2022 - 12/2009
13	RelaxinIBA 12/2021 - 04/2009
13	Warfarin (Coumadin)FDA LinkGeneric 04/2019 - 05/2012
13	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 04/2019 - 05/2012
12	Pharmaceutical PreparationsIBA 10/2021 - 01/2010
11	Natriuretic PeptidesIBA 01/2022 - 03/2016
9	Purinergic P1 Receptor AntagonistsIBA 11/2019 - 05/2011
9	Urea (Carbamide)FDA LinkGeneric 01/2017 - 01/2014
8	CreatinineIBA 01/2022 - 01/2013
8	NitrogenIBA 01/2017 - 01/2014
7	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2019 - 08/2005
7	tezosentanIBA 01/2017 - 07/2003
6	sacubitril and valsartan sodium hydrate drug combinationIBA 11/2020 - 01/2015
6	Neprilysin (Neutral Endopeptidase)IBA 06/2019 - 01/2015
6	Angiotensin Receptors (Angiotensin II Receptor)IBA 06/2019 - 01/2015
6	Vasodilator Agents (Vasodilators)IBA 01/2017 - 05/2004
5	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/2019 - 08/2005
5	Angiotensin Receptor AntagonistsIBA 11/2019 - 08/2005
5	Endothelin Receptors (Endothelin Receptor)IBA 01/2017 - 07/2005
5	TroponinIBA 01/2017 - 01/2011
5	Tolvaptan FDA Link 01/2016 - 05/2004
5	Troponin T (Troponin T1)IBA 01/2016 - 11/2011
4	empagliflozinIBA 01/2022 - 01/2021
4	Furosemide (Lasix)FDA LinkGeneric 01/2022 - 05/2014
4	Sodium-Glucose Transport ProteinsIBA 01/2022 - 12/2019
4	Enalapril FDA LinkGeneric 10/2017 - 01/2015
4	Simendan (Levosimendan)IBA 04/2013 - 05/2004
4	Adenosine (Adenocard)FDA LinkGeneric 03/2012 - 05/2004
4	Vasoconstrictor AgentsIBA 06/2008 - 05/2002
4	Neurotransmitter Agents (Neurotransmitter)IBA 12/2005 - 05/2002
4	Endothelins (Endothelin)IBA 12/2005 - 05/2002
3	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 01/2021
3	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2022 - 06/2013
3	IvabradineIBA 11/2021 - 09/2010
3	PotassiumIBA 11/2021 - 01/2017
3	SodiumIBA 01/2021 - 01/2014
3	Nitroglycerin (Dynamite)FDA LinkGeneric 01/2021 - 05/2004
3	Myosins (Myosin)IBA 12/2020 - 12/2016
3	Mineralocorticoid Receptor AntagonistsIBA 11/2019 - 04/2012
3	LigandsIBA 02/2018 - 03/2015
3	MicroRNAs (MicroRNA)IBA 12/2016 - 01/2016
3	Adenosine A1 ReceptorIBA 11/2016 - 05/2011
3	Hemoglobins (Hemoglobin)IBA 02/2016 - 05/2013
3	Vasopressins (Vasopressin)IBA 01/2016 - 05/2004
3	Milrinone (Primacor)FDA LinkGeneric 10/2011 - 05/2004
3	Endothelin-1 (Endothelin 1)IBA 01/2011 - 07/2005
3	Endothelin Receptor AntagonistsIBA 11/2007 - 12/2002
2	Plant NectarIBA 01/2022 - 01/2020
2	Oxygen (Dioxygen)IBA 08/2021 - 01/2019
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2011
2	nitroxylIBA 01/2021 - 01/2019
2	Biological ProductsIBA 01/2021 - 01/2019
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2010
2	Hypoglycemic Agents (Hypoglycemics)IBA 12/2019 - 10/2017
2	Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OHIBA 02/2018 - 03/2015
2	Type 1 Angiotensin ReceptorIBA 02/2018 - 08/2017
2	salicylhydroxamic acid (SHAM)IBA 11/2017 - 03/2017
2	C-Reactive ProteinIBA 02/2016 - 01/2011
2	AlbuminsIBA 01/2016 - 01/2014
2	Irbesartan FDA LinkGeneric 06/2015 - 03/2010

Therapy/Procedure

61	Therapeutics 01/2022 - 02/2003
24	Patient Readmission 01/2022 - 04/2010
16	Length of Stay 01/2020 - 01/2010
3	Critical Care (Surgical Intensive Care) 10/2021 - 01/2015
3	Intravenous Infusions 01/2019 - 01/2013
2	Vagus Nerve Stimulation 01/2022 - 01/2020
2	Heart Transplantation (Grafting, Heart) 09/2019 - 01/2015
2	Investigational Therapies (Experimental Therapy) 11/2015 - 02/2015